The first trial was an investigator-initiated, randomized controlled study designed to evaluate the safety and efficacy of single-dose DPSC therapy, conducted at Beijing Stomatological Hospital from May 22, 2020, to February 16, 2023 (Ethical code: CMUSH-IRB-KJ-PJ-2019-14)
This strategy combines upscaling the tool through the creation of a Community of Practice (CoP) at the Mediterranean level and downscaling it to new contexts, including Croatia, Portugal, Albania, and regions in the South and Middle East Mediterranean
A 5 mg vial reconstituted to 10 mg/mL yields 3.8 mg of withdrawable drug [1]
But not everyone who feels tired is B12 deficient, and not everyone with low B12 requires an injection
Our mission is to provide just that
Tirzepatide with B12 has become one of the most popular compounded formulations specifically because of this anti-nausea benefit